Why is Cohance Life falling/rising?

As of 29-Aug, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 876.60, which reflects a decrease of -2.25 (-0.26%). The stock has underperformed its sector by -0.29% today and has been on a consecutive downward trend for the last three days, resulting in a total loss of -2.4% during this period. Additionally, the stock is trading close to its 52-week low, just 2.25% away from Rs 856.9. Over the past month, the stock has seen a significant decline of -12.99%, while its year-to-date performance shows a drop of -22.65%. Despite high management efficiency indicated by a return on equity (ROE) of 24.14% and a low debt-to-equity ratio, the stock faces challenges such as poor long-term growth, with operating profit growing at only 2.95% annually over the last five years. Furthermore, the company's recent quarterly results show a substantial decline in profit after tax (PAT) by -41.1%, contributing to a perception of an expensive valuation compared to peers.
In the broader market context, while the Sensex has experienced a decline of -1.84% over the past week, Cohance Lifesciences Ltd has fared slightly better with a smaller drop of -1.18%. However, the stock's performance over the last year has been significantly worse than the market, with a return of -17.61% compared to the BSE500's -5.40%. The increase in pledged promoter shares, which has risen by 100% over the last quarter, adds to the downward pressure on the stock, particularly in a falling market. This combination of poor recent performance, high valuation concerns, and increased risk from pledged shares contributes to the stock's current decline.